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Romidepsin (RMD) is a well-characterized histone deacetylase inhibitor approved for the
treatment of cutaneous T-cell lymphoma. in vitro and in vivo studies have demonstrated
that it is able to induce HIV-1 gene expression in latently infected CD4+ T cells from
HIV-1+ individuals on suppressive antiretroviral therapy. However, in vitro experiments
suggested that RMD could also impair T-cell functionality, particularly of activated T
cells. Thus, the usefulness of RMD in HIV-1 kick&kill strategies, that aim to enhance the
immune system elimination of infected cells after inducing HIV-1 viral reactivation, may
be limited. In order to address whether the in vitro observations are replicated in vivo,
we determined the effects of RMD on the total and HIV-1-specific T-cell populations
in longitudinal samples from the BCN02 kick&kill clinical trial (NCT02616874). BCN02
was a proof-of-concept study in 15 early treated HIV-1+ individuals that combined
MVA.HIVconsv vaccination with three weekly infusions of RMD given as a latency
reversing agent. Our results show that RMD induced a transient increase in the frequency
of apoptotic T cells and an enhanced activation of vaccine-induced T cells. Although
RMD reduced the number of vaccine-elicited T cells secreting multiple cytokines, viral
suppressive capacity of CD8+ T cells was preserved over the RMD treatment. These
observations have important implications for the design of effective kick&kill strategies
for the HIV-1 cure.
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INTRODUCTION
Current antiretroviral therapy (ART) effectively suppresses HIV-1 replication in plasma, but it is
not able to completely eliminate the virus from infected individuals. Cessation of antiretroviral
treatment results in a rebound of plasma viremia within 3–4 weeks in most individuals (1). This
rapid viral rebound after treatment interruption is due to the existence of a latent viral reservoir
Rosás-Umbert et al. Romidepsin Effects on Vaccine-Induced T-Cells
and the inability of the immune system to effectively contain viral
replication. To date, numerous strategies have been pursued to
achieve a functional cure or virus eradication, including early
ART initiation, ART intensification (2–6), passive administration
of antibodies (7), therapeutic vaccination (8–13) and gene
therapy (14, 15), among others.
HIV-1 kick&kill strategies are based on the use of latency
reversing agents (LRA) to induce production of HIV-1 proteins
in latently infected cells and render these cells susceptible to
vaccine-induced virus-specific cytolytic T lymphocytes (CTL).
The interest in LRA able to reactivate the latent provirus
has increased over the past decade, with histone deacetylation
inhibitors (HDACi) being some of the best characterized agents
both in vitro and in vivo. The inhibitory effect of HDACi on
histone deacetylation results in a higher degree of acetylated
histones, causing opening of chromosomes and increased gene
transcription. In ex vivo isolated cells from ART-suppressed
HIV-1-infected individuals, exposure to HDACi resulted in
reactivation of the integrated HIV-1 and led to viral protein
expression by latently infected cells (16–18). Some HDACi, such
as vorinostat (SAHA), panobinostat, and romidepsin (RMD)
have also been tested for their in vivo potential to reverse
HIV-1 latency (19–22). RMD, a cyclic depsipeptide naturally
produced by Chromobacterium violaceum, is a pan-HDACi
that inhibits class I HDACs. RMD was clinically developed
as an anti-cancer drug and is approved for the treatment of
cutaneous T-cell lymphoma (23). Furthermore, RMD has been
shown to induce HIV-1 gene expression in latently infected
cells in vitro (18, 24) and in vivo, when administrated alone
(22) and in combination with therapeutic vaccine Vacc-4x (25)
in chronically-infected ART-suppressed individuals. Although it
was first thought that reactivation of the virus itself would lead to
robust immune activation and control of the rebounding virus,
it is generally accepted that prior stimulation of the immune
effector response by a therapeutic vaccine and/or an immune
checkpoint inhibitor, may be needed in order to efficiently
eliminate infected cells after LRA exposure (26). Therefore,
different immunotherapies are being investigated together with
LRAs to test their combined effect, especially combination
treatments that include T-cell vaccines.
FIGURE 1 | Study design. The BCN02 study was a single arm, open label, proof-of-concept study to address safety and effect on the viral reservoir of a kick&kill
strategy combining MVA.HIVconsv vaccines with the HDACi RMD. Timepoints used for the analysis presented here are indicated for each assay by filled circles.
The proof-of-concept BCN02 trial evaluated a kick&kill
strategy that combined the HIVconsv T-cell vaccines with
the HDACi RMD in a cohort of early-treated, HIV-1-
infected individuals. Fifteen participants of BCN01 (12),
who previously received simian adenovirus-vectored vaccine
ChAdV63.HIVconsv andMVA.HIVconsv, were invited 2–3 years
later to receive two more dosing of the MVA.HIVconsv vaccine
before (MVA1) and after (MVA2) three weekly-doses of RMD
(RMD1−2−3) followed by a monitored antiretroviral pause
(MAP) for a period of 32 weeks (NCT02616874). The combined
strategy was proven to be safe and vaccination was highly
immunogenic. RMD treatment resulted in marked increases
in histone acetylation and cell-associated HIV-1 RNA levels
compatible with induction of viral transcription. However, the
ultimate reduction of the viral reservoir in the BCN02 trial was
overall minimal (27). Aside from effects on virus reactivation, for
a successful purge of the viral reservoir, it is critical that the LRA
used in such strategies does not have any detrimental effects on
the vaccine-induced immune cells (28, 29). Here, we assessed the
in vivo impact of three weekly RMD doses on total and vaccine-




The BCN02 clinical trial (NCT02616874) was a phase I, open-
label, single-arm, multicenter study in Spain (27). The study
was approved by the institutional ethical review board of the
participating institutions (Reference Nr AC-15-108-R) and by
the Spanish Regulatory Authorities (EudraCT 2015-002300-84)
and was conducted in accordance with the principles of the
Helsinki Declaration and local personal data protection law
(LOPD 15/1999). Fifteen participants were immunized with
MVA.HIVconsv (MVA1, 2 × 108 pfu intramuscularly), followed
by three weekly-doses of romidepsin (RMD1−2−3, 5 mg/m2
body-surface area; BSA) and a second MVA.HIVconsv boost
vaccination (MVA2, 2 × 108 pfu i.m.) before undergoing a
monitored antiretroviral pause (MAP) 8 weeks later and for
a maximum of 32 weeks. Cryopreserved peripheral blood
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mononuclear cells (PBMC) were stored before, at the end and
after 8, 24 h (only for RMD1), and 3 and 7 days after all RMD
doses for immunological and virological studies.
Flow Cytometry
Apoptosis Measurement
PBMC viability was measured using a Pacific BlueTM Annexin
V Apoptosis Detection Kit with 7-AAD (BioLegend). Lineage
surface markers (CD3, CD4, and CD8) and activation markers
(HLA-DR, CD25, and CD69) were included in the staining.
Briefly, 1 × 106 of isolated PBMC were washed in PBS with
1% FBS and resuspend in 100 µl of surface staining solution
(CD3, CD4, CD8, CD25, CD69, HLA-DR) and incubated for
20min. After 2 washes with 300 µl of PBS with 1% FBS, cells
were resuspended in 100 µl of Annexin V Binding Buffer with
the corresponding Annexin V and 7-AAD. After 15min of
incubation, 250 µl of Binding Buffer was added to each tube and
acquired on a LSRII BD cytometer. The percentages of apoptotic
and live cells were analyzed using FlowJo software. The gating
strategy is summarized in Supplementary Figure 1.
T Cells and HIVconsv-Specific T-Cell Lineage,
Activation and Cytokine Detection
PBMCs were thawed and stimulated with anti-CD49d and anti-
CD28 antibodies (BD) in presence/absence of three peptides
pools (containing 58, 54, and 54 peptides) covering the HIVconsv
immunogen protein in the presence of GolgiStop for 5 h.
Cultures were then stored overnight at 4◦C until staining.
Cells were stained first with a viability stain (Aqua Live/Dead
Fixable Dead Cell Stain kit, Invitrogen), followed by T cell
lineage and maduration/activation markers (using anti-CD3-
APC Cy7, anti-CD4 PECy5; anti-CD8 PerCP, anti-CCR7 B711,
anti-CD45RA BV785, anti-HLA-DR BV650, anti-PD-1 BV605,
anti-CD69 APC, and anti-CD25 PEDazzle594 chromogen-
conjugated monoclonal antiobodies; BioLegend) and dump
channel (using anti-CD19-V450 for B-cells and anti-CD14-V450
mAbs for monocytes; BioLegend) surface staining. Following
the fixation and permeabilization step (Fix and Perm kit,
Invitrogen), intracellular staining with conjugated antibodies
specific for cytokines (IFN-γ A700; Invitrogen, IL-2 PECy7,
TNF-α FITC; BiolLegend and MIP1-β PE; RD Systems) was
performed. Approximately 105 cells were acquired on an
LSRFortessa BD instrument, and analysis was performed using
FlowJo 10 software. The gating strategy is summarized in
Supplementary Figure 2.
Intracellular cytokine staining analyses were done applying
boolean gates in FlowJo 10, subtracting unstimulated signals
using Pestle v1.7 program and represented using SPICE v5.35
software (provided by the National Institute of Health, Mario
Roeder, ImmunoTechnology Section, Vaccine Research Center,
NIAID, NIH, Bethesda) (30).
Viral Inhibition Assay
CD8+ T-cell mediated viral inhibition capacity was measured at
1:1 and 1:10 CD8 effector to CD4 target ratios. Cryopreserved
PBMCs were obtained from timepoints before the BCN02
intervention and CD8+ cells were depleted by magnetic bead
separation (MACSMilteny Biotec). CD8+-depleted cells (CD4+-
enriched fraction) were stimulated with PHA (5µg/ml) in
RPMI plus 10% fetal bovine serum (R10) and antibiotics
(penicillin 100 U/mL and streptavidin 100µg/ml). After 3
days of stimulation, the CD4-enriched fraction was infected by
spinoculation with HIV-1BaL and HIV-1IIIB laboratory-adapted
strains at a multiplicity of infection (MOI) of 0.01 as reported
previously (12, 31). HIV-infected cells were cultured in duplicates
or triplicates in R10 medium with 20 U/ml of IL-2 in 96-well
round-bottomed plates, alone or together with unstimulated
CD8+ T cells obtained by positive magnetic bead separation the
same day from an additional vial of frozen PBMC from screening
(week −4), 3 weeks after MVA1 (week 3, postMVA1), 1 week
after RMD3 (week 6, postRMD3), 4 weeks after MVA2 (week
13, postMVA2) timepoints. Cultures at different CD8:CD4 ratios
(E:T = 1:1 and 1:10) were harvested after 6 days. Cells were
stained first with Aqua Live/Dead stained for surface markers
(CD3 APC-H7, BD Biosciences, CD4 PerCP, BD Biosciences, and
CD8 APC, BD Biosciences), then permeabilized (FIX & PERM R©
Cell Permeabilization Kit, ThermoFisher). Cells were then fixed
(FIX & PERM R© Cell Permeabilization Kit, ThermoFisher) at
room temperature and finally stained with anti-Gag p24 antibody
(KC-57-FITC; Beckman Coulter). CD8+ T-cell antiviral activity
is expressed as % inhibition = [(fraction of p24+ cells in CD4+
T cells cultured alone)–(fraction of p24+ cells in CD4+ T cells
cultured with CD8+ T cells)]/(fraction of p24+ in CD4+ T cells
cultured alone) × 100. At least 100,000 cells were collected on
a LSRII BD cytometer and analysis was performed using FlowJo
10 software.
Statistical Analysis
GraphPad Prism version 7 for Windows (San Diego, CA) was
used for statistical analysis. Mann-Whitney test and Wilcoxon
matched paired test were used for unpaired and paired
comparisons, respectively. Significant values were considered
for p <0.05.
RESULTS
Increased Apoptosis After RMD Exposure
Since RMD was previously described to have a toxic effect in
vitro (28, 29), especially on activated T cells, we first measured
the effect of RMD on cell viability both in total CD8+ and
CD4+ T cells and in activated, HLA-DR+ expressing cells in
PBMC from the BCN02 participants. Viability in total T cells
was assessed by flow cytometry by Annexin V/7AAD staining
before and after the three RMD doses. Increases in the number of
apoptotic CD8+ T cells (Annexin V+) were detected at 24 h after
RMD1 (Wilcoxon signed-rank, p= 0.0151) and 3 days after each
RMD dose (Wilcoxon signed-rank, RMD1 p = 0.0413, RMD2
p = 0.0181, and RMD3 p = 0.0833, respectively, Figure 2A). A
similar pattern was observed in CD4+ T cells, with apoptotic
cells being significantly increased 3 days after RMD2 and RMD3
(Wilcoxon signed-rank, RMD2 p= 0.0067 and RMD3 p= 0.0413,
respectively, Figure 2B). One week after RMD3 the levels of
apoptotic cells in both CD8+ T cells and CD4+ were not restored
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FIGURE 2 | Effect of RMD on the viability on T cells. Apoptotic cells (Annexin V+/7AAD+ and Annexin V+/7AAD−) percentages are shown for CD8+ (A) and CD4+ T
cells (B). Changes relative to baseline in the percentage of apoptosis in HLA-DR+ (in red) and HLA-DR− cells (in purple) are shown for CD8+ (C) and CD4+ (D) T cells.
RMD administration cycles are indicated by gray bars. Sampling time points at 4 h, 8 h, 3 days, and 7 days after each RMD administration are indicated. Median with
interquartile range is shown. P-values (*p < 0.05, **p < 0.01, ***p <0.001) are indicative for the corresponding timepoint compared to pre-RMD1.
to pre-RMD levels (p = 0.0054 for CD8+ and p = 0.0181 for
CD4+), suggestive of an accumulative toxic effect of RMD.
As activated T cell have been found to be particularly sensitive
to RMD exposure (28), levels of apoptosis in CD4+ and CD8+
T cell with high or low expression of the activation marker
HLA-DR were assessed. Changes in the percentage of apoptotic
cells relative to baseline during RMD exposure was comparable
between HLA-DR+ and HLA-DR− CD8T cells (Figures 2C,D).
The same results were observed in CD4+ T cells. Therefore,
non- activated HLA-DR− cells had the same susceptibility to
induction of apoptosis due to RMD exposure as the activated
HLA-DR+ cells.
CD8+ and CD4+ Naïve Populations
Increase After MVA1 and Up to 24h After
1st Romidepsin Exposure Followed by a
Shift to Memory Phenotypes
As activation status did not impact susceptibility of T cells to
RMD-induced apoptosis, we next assessed whether RMD could
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FIGURE 3 | Evolution of T-cell subsets over the course of the intervention. Averages of relative frequency of CD8+ (A) and CD4+ (B) T-cell subsets based on CCR7
and CD45RA expression are shown. TEMRA: highly differentiated effector cells expressing CD45RA (CCR7−/CD45RA+), EM: effector memory cells
(CCR7−/CD45RA−), CM: central memory (CCR7+/CD45RA−), and naïve (CCR7+/CD45RA+). P-values (*p < 0.05, **p < 0.01, ***p < 0.001) are indicative for the
corresponding timepoint compared with values from baseline samples prior to MVA1.
affect the distribution of different T-cell differentiation subsets in
the peripheral blood. Flow cytometry was used to measure the
frequency of CD4+ and CD8+ differentiation subsets defined by
CCR7 and CD45RA expression at each timepoint. Three weeks
after MVA1, the frequency of naïve CD8+ T cells increased
from median frequency of 30.5–35.2% and up to 49.6% 24 h
after RMD1 (Wilcoxon signed-rank p = 0.0122 and p = 0.0005,
respectively, Figure 3A). Similar results were observed for naïve
CD4+ T cells, which increased from 33% at baseline to 35.2%
3 weeks after MVA1 and up to 41.7% at 24 h after RMD1
(Wilcoxon signed-rank p = 0.0227 and p = 0.0110, respectively,
Figure 3B). The frequency of CD8+ and CD4+ naïve cells were
not further increased after RMD2 or RMD3, as their frequency
actually decreased after RMD2 and RMD3. At the same time, the
median frequency of CD8+ effector memory and CD4+ central
memory T cells progressively increased over RMD1−2−3. T-cell
differentiation subsets were not further changed 4 weeks after
MVA2 compared to subset population observed after RMDdoses.
RMD Treatment Increases T-Cell Activation
Especially of the HIVconsv-Specific T Cells
In order to assess the effect of RMD on T-cell activation and
exhaustion markers, we evaluated the frequency of CD4+ and
CD8+ T cells expressing HLA-DR, CD69, CD25, and PD-1. A
peak in the frequency of CD8+HLA-DR+ T cells was observed
3 days after RMD1 (Wilcoxon signed-rank, p < 0.0001) and
increased levels were maintained over the course of the 3 RMD
doses, as their median frequency more than doubled (4.1% at
baseline to 9.6% 1 week after RMD3, Wilcoxon signed-rank,
p = 0.0002, Figure 4A). The same results were observed in
CD4+ T cells, with levels of HLA-DR expression increasing
3 days after RMD1 (Wilcoxon signed-rank, p < 0.0001) and
with twice as many HLA-DR expressing cells at day 7 after
RMD3 (median 3.1% at baseline to 6.3%, Wilcoxon signed-
rank, p = 0.0017, Figure 4A) compared to baseline. The largest
increase in percentage of cells expressing HLA-DR in both CD4+
and CD8+ T cells was observed in effector memory (EM) and
highly differentiated effector cells expressing CD45RA (TEMRA)
(Supplementary Figure 3).
Importantly, upon in vitro stimulation with peptides derived
from the vaccine immunogen, changes in the HLA-DR+ in
expression were already detected after MVA1. Both, HIVconsv-
specific CD8+ and CD4+ T cells, defined upon in vitro antigen-
specific stimulation and detection based on their ability to
produce cytokines (IL-2, MIP1-β, TNF-α, IFN-γ) in response to
antigen specific stimulation, showed detectable increases of HLA-
DR+ expression earlier and up to higher levels compared to the
changes seen in total CD8+ and CD4+ T cells (Figure 4A). The
percentage of HLA-DR+ among HIVconsv-specific CD8+ cells
increased from median of 5.1% at baseline to 10.11% 3 weeks
after MVA1, and up to 21% 3 days after RMD1 (Wilcoxon signed-
rank p = 0.0245 and p = 0.0002, Figure 4B) and percentage
of HLA-DR+, HIVconsv-specific CD4+ cells increased from
median of 4.2% at baseline to 8.3% 3 weeks after MVA1, and
up to 21.8% 3 days after RMD1 (Wilcoxon signed-rank p =
0.5614 and p= 0.0023, Figure 4C). High levels of activation were
maintained during all RMD doses (Figures 4C,D) and reached
the peak 3 days after RMD3 suggestive of an additive effect of
RMD on the activation of vaccine-stimulated CD4+ and CD8+
T cells.
As changes in in vivo histone acetylation and induction of
viral transcription occur rapidly after RMD exposure (22, 27),
we assessed the expression of early activation markers CD69 and
CD25 in CD4+ and CD8+ T cells. Increases in the expression of
CD69 in CD4+ T cells were observed upon each RMD dosing,
with significant increases seen after RMD2 and RMD3 in the
CM subset (from baseline levels of 2.5 to 7.1% (RMD2 p =
0.0107) and 6.7% (RMD3 p = 0.0479) and in the TEMRA subset
(baseline levels of 2.7 to 9% (RMD2 p = 0.0203) and 6.6%
(RMD3 p = 0.0315), respectively (Supplementary Figure 4B).
As with HLA-DR surface staining, expression of CD69 returned
to baseline levels 4 weeks after last vaccination. No significant
changes were observed in CD69 expression on CD8+ T cells
(Supplementary Figure 4A) nor in the expression of CD25 on
CD8+ or CD4+ T cells over the course of the intervention.
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FIGURE 4 | CD4+ and CD8+ T cell activation status over the course of the intervention. Percentage of HLA-DR expression is shown for CD8+ in orange and CD4+ T
cells in purple (A). Levels of HLA-DR are shown for CD8+ (B) and CD4+ T cells (C) in HIVconsv specific and total T cells. HIVconsv-specific T cells were defined upon
in vitro antigen-specific stimulation and detection based on their ability to produce cytokines (IL-2, MIP1-β, TNF-α, IFN-γ) in response to stimulation. Percentage of
PD-1 is shown for CD8+ in orange and CD4+ T cells in purple (D). Median with interquartile range is shown. P-values (*p < 0.05, **p < 0.01, ***p < 0.001, ****p <
0.0001) are indicative for the corresponding timepoint compared with baseline.
The expression of PD-1+ increased rapidly in CD8+ T cells
from median baseline levels of 4.6–6.4, 7.2, and 6.1% at 4 h after
the end of RMD1−2−3 treatment (Wilcoxon singed-rank, p =
0.0215, p = 0.0238, and p = 0.0574, respectively, Figure 4D).
The same kinetics was observed in CD4+ T cells where the
frequency of PD-1 expressing cells raised from median baseline
levels of 8.5–11.9, 12.35, and 10.7% at 4 h after RMD1−2−3
(Wilcoxon singed-rank, p = 0.0004, p = 0.0002, and p = 0.0046,
respectively, Figure 4D). However, in contrast to the additive
effect of RMD1−2−3 on T-cell activation markers, changes in
PD-1 expression in both CD8+ and CD4+ T cells were transient,
and the levels of PD-1 expression were consistently restored to
baseline levels within 3 days after each RMD dose.
Polyfunctionality of HIVconsv-Specific
Responses Increases After MVA1 and
Decreases Over RMD Treatment
Considering the effect of RMD on the expression of markers
of cell death, exhaustion and activation, we assessed the
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FIGURE 5 | Longitudinal assessment of the T-cell cytokine production over the course of the intervention. Polyfunctionality of CD8+ and CD4+ T cells was analyzed
by Boolean gating. Pie charts illustrate relative proportion of each of the different subsets (cells producing 1, 2, 3, or 4 cytokines, respectively).
effect of RMD on the functionality of vaccine-elicited T cells.
Polyfunctionality of HIVconsv-specific T cells was measured
by stimulation of PBMC with the HIVconsv peptides and
enumeration of the cells producing IFN-γ, IL-2, MIP1-β,
and/or TNF-α by flow cytometry. As shown in Figure 5,
MVA1 vaccination increased relative polyfunctionality in both
CD4+ and CD8+ HIVconsv-specific T cells. Three weeks after
MVA1 (postMVA1), the highest increase in polyfunctionality
was observed in vaccine immunogen-specific CD4+ T cells
that produced 2, 3, and 4 cytokines (post MVA1, Figure 5),
with a particular increase in INF-γ secreting cells. On the
other hand, vaccine-specific CD8+ T cells produced INF-γ,
IL-2, and TNF-α and were mostly polyfunctional, producing
2 or 3 cytokines. However, during the treatment with RMD,
the polyfunctionality was reduced to baseline levels in both
HIVconsv-specific CD4+ and CD8+ T cells and the final MVA2
vaccination was not able to re-boost functionality profiles (post
MVA2, Figure 5 and Supplementary Figure 5). These results
suggest that RMD treatment might have impaired functionality
of vaccine-induced responses and prevented their subsequent
booster vaccination effect.
CD8+ Cells Maintain Antiviral Activity of
After the RMD Treatment
To further study the functionality of vaccine-induced T cells
during the intervention, we measured the in vitro antiviral
capacity of CD8+ T cells. The in vitro replication inhibition
capacity of PBMC-derived CD8+ T cells was measured by
standard viral inhibition assay (VIA) (12, 31) using autologous
CD4+ T cells infected with two laboratory-adapted HIV-1
strains BaL (R5 tropic virus) and IIIB (X4 tropic virus). Virus
replication was measured by flow cytometry as the percentage
of HIV-1 Gag p24-positive CD4+ cells. CD8+ T-cell inhibitory
capacity was determined at screening, 3 weeks after MVA1
(postMVA1), 1 week after RMD3 (postRMD3), and 4 weeks
after MVA2 (postMVA2). In contrast to the changes in cytokine
production/polyfunctionality detected by flow cytometry, neither
MVA1 nor RMD1−2−3 altered the inhibition activity, which
was median of 64, 52, and 53,5% at the screening, postMVA1
and postRMD3 time points at the E:T ratio 1:1, respectively,
against HIV-1BaL and median 46, 44, and 43% at the screening,
postMVA1 and postRMD3 time points, respectively, against HIV-
1IIIB. In fact, there was a weak, but statistically significant increase
in the inhibitory capacity against HIV-1BaL after the secondMVA
vaccination given 4 weeks after RMD3 from median of 64% at
baseline to 69% at postMVA2 at the E:T ratio 1:1 and frommedian
of 11% at baseline to 21% at postMVA2, for the E:T ratio1:10
(Wilcoxon signed-rank, p = 0.0200) (Figure 6A) and against
HIV-1IIIB from median of 12% at baseline to 16% at postMVA2,
for at the 1:10 E:T ratio (Wilcoxon signed-rank, p = 0.0156)
(Figure 6B). These data indicate that antiviral activity, measured
by VIA with laboratory-adapted viral strains, was not negatively
impacted during RMD treatment.
DISCUSSION
The BCN02 study was an HIV-1 kick&kill proof-of-concept trial
combiningMVA.HIVconsv vaccines with theHDACi RMDgiven
as an LRA to the previous ChAdV63.HIVconsv-MVA.HIVconsv
regimen recipients from the parental BCN01 trial (12). The
immune analyses in BCN02 showed a highly significant shift
of HIV-1-specific T-cell responses toward conserved regions of
HIV-1 covered by the immunogen and marked increases in
histone acetylation and induction of viral transcription in vivo by
RMD. However, the reduction of the viral reservoir after these
interventions was overall minimal (27). Already low baseline
levels of viral reservoir in the early-treated participants enrolled
in the BCN02 study likely limited latency reversal activity of
RMD and/or a potential toxicity of RMD (28, 32) on vaccine-
induced T cells might have precluded the capability to observe
a more pronounced reduction in the size of the viral reservoir.
To address the latter possibility, we here evaluated the effect
that the HDACi RMD had on the T-cell viability, activation and
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FIGURE 6 | In vitro viral replication inhibition capacity. Levels of CD8+ viral inhibitory capacity are shown for HIV-1BaL (A) and HIV-1IIIB (B) at two E/T ratios
(effector/target ratio) 1:1 and E/T 1:10 in individuals that underwent the intervention (n = 14 for HIV-1BaL and n = 15 for HIV-1IIIB). P-values (*p < 0.05) are indicative
for the corresponding timepoint compared with respective bsl.
functionality throughout the intervention that included RMD
given in a three weekly 5 mg/m2 BSA regimen.
Our data document a in vivo toxic effect of RMD on T
cells 3 days after each RMD exposure. Although these effects
were transient and viability of T cells was partially recovered
7 days after RMD1 and RMD2, there was an additive increase
in apoptosis over the full RMD regimen, which was not fully
restored by 7 days after RMD3. Jones et al. and Zhao et al. have
described increases in cell death upon long term (18- and 72- h
period) in vitro exposure to RMD, but no cytotoxic effect were
observed when T cells were exposed to RMD for 4 h only, which
is more similar to the in vivo regimen where the terminal half-life
(t1/2) of RMD is estimated to be ∼3 h (28, 32). Indeed, Clutton
et al. exposed ex vivo PBMC to RMD for 3 h, washed them
and cultivated them further in the absence of RMD for 3 days
in order to mimic in vivo exposure, and reported that the cell
viability was not changed after 3 or 24 h, but was significantly
reduced at 48 and 72 h (33). These results concur with our
observations showing a peak of apoptotic T cells 3 days after
each RMD infusion and could explain the transient decreases in
peripheral CD4+ T-cell counts observed in BCN02 (27). Also, the
cumulative effect on viability observed after 3 RMD doses is in
line with the delayed effects of RMD suggested by Clutton.
As RMDmay induce T-cell activation resulting from reservoir
reactivation and viral antigen presentation, which could also
drive increase in exhaustion levels prior to the induction of
apoptosis, we evaluated the frequency of activated CD4+ and
CD8+ T cells. Indeed, the additive increase in HLA-DR+
activation markers in both CD8+ and CD4+ T cells over RMD
treatment, especially in HIVconsv-specific T cells, was already
observed after the first MVA.HIVconsv vaccination. Moreover, as
the increased expression of HLA-DR was mostly observed in T
effector memory cells and the fact that HIVconsv-specific T cells
showed higher levels of HLA-DR expression, the data suggest
that there could be a different memory distribution among
HIVconsv-specific T cells compared to the total T cell population.
These changes are in line with the increase in the magnitude
of the immunogen-specific responses upon vaccination (27).
However, the magnitudes of vaccine-specific responses were not
increased further during RMD administration, suggesting that
viral reactivation did not contribute in a major way to the
increased levels of cell activation during RMD. In contrast, RMD
treatment changed levels of CD69 and PD-1 more rapidly albeit
transiently, peaking at 4 h after the end of each RMD dose. In
line with our observation on CD69 longitudinal expression, an
increase in CD69+ expression was previously described upon
RMD, panobinostat and vorinostat treatments in vitro (18, 24)
and also in vivo given alone (22) or in combination with a vaccine
(34). This enhanced expression of PD-1 and CD69 could be the
result of a generalized increased expression of the host genes
induced by the action of RMD. So far, little is known about
the effect of RMD and other LRA on the host genome gene
expression profiles. There is an urgent need to better understand
these effects and, especially, to clarify how they can affect the
antiviral immunity against HIV-1 (35) or, in fact, fueling it.
Although it was previously described that RMD can impair
T-cell and NK function in vitro (28, 29, 36, 37), Søgaard et al.
presented in vivo data from the REDUC trial, indicating that
RMD did not alter the proportion of HIV-1-specific T cells
nor inhibited T-cell cytokine production (22), at least in the
peripheral blood. Nonetheless, there appears to be a trend
toward decreased HIV-specific T cell responses after RMD
treatment, which may have not reached statistical significance
due to the limited group size. On another note, vaccine-
induced responses in the REDUC trial were weaker compared
to the responses induced in the BCN02 trial (12, 27), possibly
due to weaker vaccine vectors/immunogens employed in the
REDUC trial. In addition, REDUC did not include early-treated
individuals with relatively intact immunity, and the detection of
reduced polyfunctionality of vaccine-induced T-cells could have
been limited. In BCN02, the first MVA.HIVconsv vaccination
enhanced polyfunctionality, especially in CD4+ T cells, in line
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with previous reports showing that MVA-vectored vaccination
can improve the polyfunctionality and T effector memory
phenotype in CD4+ T cells more so than in CD8+ T cells (38).
This increased effector function profile induced by MVA1 was
reduced upon RMD treatment but did not lead to a net reduction
of the latent reservoir compared to baseline.
Our data also indicate that despite fluctuations in activation,
maturation phenotypes and polyfunctionality, RMD treatment
did not impair the in vitro antiviral capacity of CD8+ T cells.
While some in vitro studies have shown a diminished inhibitory
capacity when CD8+ T cells were exposed to RMD, but not
to other HDACi (39, 40), such an effect was not observed in
vivo in clinical trials using RMD. In the REDUC trial, the viral
inhibition assay showed a trend toward increased inhibitory
activity post-immunization that was lost after RMD exposure,
but overall, antiviral capacity did not significantly change over
time. Similarly, we did not see a reduction in the antiviral capacity
of T cells over the course of RMD1−2−3, suggesting that the
preservation of the antiviral capacity may depend on the balance
between the deleterious effects of RMD and the potency of the
employed vaccination strategy.
Of note, our results highlight that there is no direct
comparability between assays used to characterize CTL
functionality, including multiparametric flow cytometry and
in vitro inhibition assays. In particular, in our study, the
polyfunctionality of CD8+ T cells decreased slightly during
RMD treatment, while in vitro VIA activity was maintained.
In addition, the MVA2 boost vaccination did not augment
the proportion of cell secreting multiple cytokines, while a
moderately increased in vitro suppressive capacity was observed.
These data are consistent with other studies, which showed a
disconnection between cytokine secretion and antiviral capacity
(41, 42), indicating that polyfunctionality of HIV-1-specific
CD8+ T cells (at least as measured in standard assays) is not
directly associated with viral suppression capacity (31, 43, 44).
This lack of consistency between the two techniques could
be due to the cytokines measured in standard protocols for
intracellular cytokine assays: whilst IFN-γ, IL-2, MIP1-β, and
TNF-α are used to measure functionality of HIV-1-specific T
cells, evaluating secretion of granzyme B and perforin could be
more accurate when assessing T-cell killing activity and may
provide better concordance with VIA activity (45). However,
whether antiviral capacity measured by standard in vitro VIA
assay using laboratory-adapted viral strains will translate into
effective in vivo killing or reactivated, HIV-1 infected cells
remain to be determined as well. In addition, further work
using autologous virus might be more representative of the
physiological conditions in kick&kill strategies. Finally, viral
suppression capacity was measured in total bulk CD8+ T cells
while cytokine secretion was measured in vaccine specific
cells, which could have been more susceptible to in vivo effects
by RMD.
This present study has a number of limitations, which include
a small sample size and the lack of control arms, both placebo
and single intervention arms to discern the effects exerted by
RMD or the vaccine alone. Thus, the presented results need to
be interpreted with caution. Still, the present study shows that
RMD has a transient effect on T-cell viability, exhaustion and
increased cell activation in an additive way over three weekly
doses. Although this can result in a decrease of polyfunctionality
of vaccine-induced HIVconsv-specific responses, the in vitro
replication inhibition capacity of CD8+ T cells was not impaired
and should not preclude effective killing upon RMD-induced
viral reactivation. As RMD increased higher levels of HIV-1
transcription on the RMD2 and RMD3 dose, it is tempting
to speculate that increasing the number the RMD doses could
result in further increased in levels of reservoir reactivation
without overly inhibiting the antiviral capacity of CD8+ T
cells. Regardless whether this would occur in vivo with longer
term RMD administration, the present data indicate that
timing and order of LRA and T-cell immunotherapy regimens
are critical in order to achieve the clearance of reactivated
latently HIV-1-infected cells. Larger controlled clinical trials are
needed to further investigate combinations of LRA and immune
intervention in order to find the best strategy to achieve a
functional cure of HIV-1.
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